Lonza Extends Manufacturing Deal with Elusys

Lonza says it has signed an agreement with biopharmaceutical company Elusys Therapeutics (Pine Brook, NJ), for the scale-up and commercial production of therapeutic monoclonal antibody Anthim. Anthim is in late-stage development for the treatment of inhaled anthrax. Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the U.S., according to the new contract. The manufacturing process for Anthim was optimized for full-scale production by Lonza under an agreement signed in June 2009, and the...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers